These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11533634)

  • 1. Putting a price on biotechnology.
    Stewart JJ; Allison PN; Johnson RS
    Nat Biotechnol; 2001 Sep; 19(9):813-7. PubMed ID: 11533634
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotechnology venture capital booms in Japan.
    Saegusa A
    Nat Biotechnol; 2000 Mar; 18(3):256. PubMed ID: 10700128
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 4. Fickle financing climate continues.
    Mitchell P
    Nat Biotechnol; 2001 Aug; 19(8):695-6. PubMed ID: 11479542
    [No Abstract]   [Full Text] [Related]  

  • 5. Are small biotechs still underselling themselves?
    Ransom J
    Nat Biotechnol; 2006 May; 24(5):477. PubMed ID: 16680112
    [No Abstract]   [Full Text] [Related]  

  • 6. Financing bonanza set to continue.
    Davidson S
    Nat Biotechnol; 2000 Sep; 18(9):922-3. PubMed ID: 10973203
    [No Abstract]   [Full Text] [Related]  

  • 7. France critiques its incubator before refinancing.
    Louët S
    Nat Biotechnol; 2004 Jan; 22(1):126. PubMed ID: 14725299
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 9. Consolidations in biotechnology.
    Persidis A
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE3-4. PubMed ID: 10052311
    [No Abstract]   [Full Text] [Related]  

  • 10. The changing attitude of European VCs.
    Mitchell P
    Nat Biotechnol; 2004 Apr; 22(4):479. PubMed ID: 15085807
    [No Abstract]   [Full Text] [Related]  

  • 11. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 12. Partnering up in Q3.
    Lawrence S
    Nat Biotechnol; 2007 Nov; 25(11):1200. PubMed ID: 17989659
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 14. This means war.
    Nat Biotechnol; 2008 Sep; 26(9):954. PubMed ID: 18779784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic consolidation: the biotechnology business model for the 21st century.
    Esposito RS; Ostro MJ
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE16-7. PubMed ID: 10052317
    [No Abstract]   [Full Text] [Related]  

  • 16. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Zealand launches biotech seed fund.
    Griggs K
    Nat Biotechnol; 2004 Apr; 22(4):480-1. PubMed ID: 15085809
    [No Abstract]   [Full Text] [Related]  

  • 18. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech IPOs: handle with care.
    Jacobs T
    Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
    [No Abstract]   [Full Text] [Related]  

  • 20. Profile: Villoo Morawala Patell.
    Jayaraman KS
    Nat Biotechnol; 2007 Jul; 25(7):705. PubMed ID: 17621282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.